Press releases
Today the subscription period of StaybIe Therapeutics AB’s rights issue starts
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, JAPAN, CANADA, NEW ZEELAND, SOUTH AFRICA, HONG KONG, SWITZERLAND,...
StaybIe Therapeutics AB receives additional pre-subscription and underwriting commitments for the upcoming rights issue
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, JAPAN, CANADA, NEW ZEELAND, SOUTH AFRICA, HONG KONG, SWITZERLAND,...
Stayble Therapeutics AB publishes prospectus relating to the rights issue
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, JAPAN, CANADA, NEW ZEELAND, SOUTH AFRICA, HONG KONG, SWITZERLAND,...
(SE) Kommuniké från extra bolagsstämma i Stayble Therapeutics AB
Idag den 16 mars 2023 hölls extra bolagsstämma i Stayble Therapeutics AB. Nedan följer en sammanfattning av de beslut som fattades. Samtliga beslut fattades med...
Stayble Therapeutics presents at the Life Science Day in Gothenburg March 8 2023
Stayble Therapeutics AB ("Stayble" or "the Company") announces that the Company will participate in the annual Life-Science Day in Gothenburg, Sweden, which takes place on...
Stayble Therapeutics receives approval to start Phase Ib clinical trial with STA363 for the treatment of herniated discs
Stayble Therapeutics AB ("Stayble" or the "Company") announces today that the Company has received approval to initiate the first clinical trial of its disc herniation...
(SE) – Kallelse till extra bolagsstämma i Stayble Therapeutics AB
Aktieägarna i Stayble Therapeutics AB, org.nr: 559024–8372, kallas härmed till extra bolagsstämma torsdagen den 16 mars 2023 kl. 14.00 i på bolagets kontor, Arvid Hedvalls...
Stayble Therapeutics AB starts development of a new clinical indication and decides on a rights issue of approximately MSEK 35.2
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, JAPAN, CANADA, NEW ZEELAND, SOUTH AFRICA, HONG KONG, SWITZERLAND,...
Stayble Therapeutics publishes year-end report for 2022
Stayble Therapeutics AB ("Stayble" or the "Company") hereby publishes its year-end report for 2022. The report is available as an attached document and on the...
Stayble Therapeutics secures all key data from ongoing Phase IIb study with STA363
Stayble Therapeutics AB ("Stayble" or the "Company") announces today that the Company's Phase IIb study has reached the follow-up goal of 100 patients completing their...
Today the subscription period of StaybIe Therapeutics AB’s rights issue starts
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, JAPAN, CANADA, NEW ZEELAND, SOUTH AFRICA, HONG KONG, SWITZERLAND,...
StaybIe Therapeutics AB receives additional pre-subscription and underwriting commitments for the upcoming rights issue
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, JAPAN, CANADA, NEW ZEELAND, SOUTH AFRICA, HONG KONG, SWITZERLAND,...
Stayble Therapeutics AB publishes prospectus relating to the rights issue
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, JAPAN, CANADA, NEW ZEELAND, SOUTH AFRICA, HONG KONG, SWITZERLAND,...
(SE) Kommuniké från extra bolagsstämma i Stayble Therapeutics AB
Idag den 16 mars 2023 hölls extra bolagsstämma i Stayble Therapeutics AB. Nedan följer en sammanfattning av de beslut som fattades. Samtliga beslut fattades med...
Stayble Therapeutics receives approval to start Phase Ib clinical trial with STA363 for the treatment of herniated discs
Stayble Therapeutics AB ("Stayble" or the "Company") announces today that the Company has received approval to initiate the first clinical trial of its disc herniation...
(SE) – Kallelse till extra bolagsstämma i Stayble Therapeutics AB
Aktieägarna i Stayble Therapeutics AB, org.nr: 559024–8372, kallas härmed till extra bolagsstämma torsdagen den 16 mars 2023 kl. 14.00 i på bolagets kontor, Arvid Hedvalls...
Stayble Therapeutics AB starts development of a new clinical indication and decides on a rights issue of approximately MSEK 35.2
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, JAPAN, CANADA, NEW ZEELAND, SOUTH AFRICA, HONG KONG, SWITZERLAND,...
Stayble Therapeutics publishes year-end report for 2022
Stayble Therapeutics AB ("Stayble" or the "Company") hereby publishes its year-end report for 2022. The report is available as an attached document and on the...